The Potential of CD4+ T cells ATP level to indicate the Progression in NSCLC Patients

Le résumé fourni par la source

Abstract Purpose A new immune function assessment method (sATPCD4) has been proposed to monitor the immune suppression status in non-small cell lung cancer (NSCLC) patients after chemotherapy. In this study, we attempted to determine the utility of this functional assay in assessing the risk of disease progression in NSCLC patients. Methods A retrospective analysis of clinical data from 89 advanced NSCLC patients who received chemotherapy at the Fifth Affiliated Hospital of Guangzhou Medical University from March 15, 2022, to March 30, 2023. These patients were divided into a disease progression group (PD, n = 21) and a disease stability group (Non-PD, n = 68). Clinical data between the two groups were compared. Receiver operating characteristic (ROC) curves were plotted to determine the thresholds of baseline peripheral blood parameters for predicting disease progression occurrence. Multivariate logistic regression analysis was employed to investigate the relationship between peripheral blood markers and the incidence of disease progression. Results After chemotherapy, there were significant differences in the mean values of WBC, nATPCD4, and sATP CD4 between patients who experienced disease progression (PD) and those who remained stable (Non-PD) (P < 0.05). In the PD group, sATPCD4 levels significantly decreased post-chemotherapy, while in the Non-PD group, sATPCD4 levels showed an increase. The threshold for predicting disease progression after chemotherapy, as determined by ROC analysis, was 224.5 ng/ml (AUC = 0.887, 95% CI, 0.811–0.963). Patients in the low-immunity group (ATP < 224.5 ng/ml) were more likely to experience disease progression compared to the high-immunity group (ATP > 224.5 ng/ml) (P < 0.0001). Multivariate logistic regression analysis indicated that sATPCD4 levels were an independent predictor of disease progression in NSCLC patients Conclusions Immune function testing has the potential to assess the risk of disease progression in NSCLC patients

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.